Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920915 | 0.86 | FLT1 (0.39) | FLT1FLT4KDRPTGDR2MAPT | |
| SCHEMBL509062 | 0.83 | SRC (0.47) | KDM4EMAPTPOLBTDP1HTR2B | |
| SCHEMBL14661250 | 0.82 | LMNA (0.42) | FLT1FLT4KDRPOLBTHRB | |
| SCHEMBL509676 | 0.79 | HSD17B10 (0.50) | POLBTSHR | |
| SCHEMBL508985 | 0.79 | PTGS2 (0.44) | MAPTL3MBTL1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL508992 | 0.79 | TSHR (0.50) | FLT1FLT4KDRTDP1TSHR | |
| SCHEMBL27761452 | 0.78 | TSHR (0.48) | TDP1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL22894914 | 0.77 | CYP1A2 (0.41) | FLT1FLT4KDRKDM4EMAPT | |
| SCHEMBL8751860 | 0.77 | ALDH1A1 (0.40) | POLBALDH1A1KMT2ACYP3A4HTT | |
| SCHEMBL13908891 | 0.76 | LMNA (0.44) | FLT1FLT4KDRMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734526-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9221832-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-2734526-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-05-28 | — | — | EP | disclosed |
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8470738-B2 | Pyridazinone compound and herbicide containing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| WO-2013014587-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-31 | — | — | WO | disclosed |
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2406232-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| EP-2188264-B1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | SUMITOMO CHEMICAL CO (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20110003692-A1 | HERBICIDALLY AND INSECTICIDALLY ACTIVE PHENYL-SUBSTITUTED PYRIDAZINONES | BAYER CROPSCIENCE AG (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010104217-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100216642-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2188264-A2 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009035150-A2 | 4-PHENYL-5-HYDROXY-3(2H)-PYRIDAZINONE DERIVATIVES AS HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | WO | disclosed |
| US-20060160847-A1 | 2,4-Dihalogen-6-(c2-c3alkyl)-phenyl substituted tetramic acid derivatives | BAYER CROPSCIENCE AG (DE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028803-A1 | PYRIDAZINONE COMPOUND AND USE THEREOF | C5, C1S, WEE1 | FLT1 4538/4885FLT4 4565/4885KDR 4055/4885 |
| US-20100216642-A1 | PYRIDAZINONE COMPOUND AND HERBICIDE CONTAINING THE SAME | WEE1, WEE2, CBR3 | FLT1 3198/4885FLT4 3360/4885KDR 3899/4885 |
| US-20110003692-A1 | HERBICIDALLY AND INSECTICIDALLY ACTIVE PHENYL-SUBSTITUTED PYRIDAZINONES | CYP4X1, PRDX1, PNPO | FLT1 4026/4885FLT4 4113/4885KDR 4388/4885 |
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | FLT1 1074/4885FLT4 1418/4885KDR 1102/4885 |
| US-20060160847-A1 | 2,4-Dihalogen-6-(c2-c3alkyl)-phenyl substituted tetramic acid derivatives | DDT, DDC, DAO | FLT1 4072/4885FLT4 3661/4885KDR 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.